Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Heat shock proteins and kidney disease: perspectives of HSP therapy.

Chebotareva N, Bobkova I, Shilov E.

Cell Stress Chaperones. 2017 May;22(3):319-343. doi: 10.1007/s12192-017-0790-0. Epub 2017 Apr 13. Review.

PMID:
28409327
2.
3.

Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.

Oaxaca DM, Yang-Reid SA, Ross JA, Rodriguez G, Staniswalis JG, Kirken RA.

Tumour Biol. 2016 Sep;37(9):12643-12654. Epub 2016 Jul 21.

4.

Heat Shock Protein (HSP) Drug Discovery and Development: Targeting Heat Shock Proteins in Disease.

Shrestha L, Bolaender A, Patel HJ, Taldone T.

Curr Top Med Chem. 2016;16(25):2753-64. Review.

6.

A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

Maddocks K, Hertlein E, Chen TL, Wagner AJ, Ling Y, Flynn J, Phelps M, Johnson AJ, Byrd JC, Jones JA.

Leuk Lymphoma. 2016 Sep;57(9):2212-5. doi: 10.3109/10428194.2015.1129536. Epub 2016 Jan 14. No abstract available.

PMID:
26764527
7.

Novobiocin Analogues That Inhibit the MAPK Pathway.

Hall JA, Seedarala S, Zhao H, Garg G, Ghosh S, Blagg BS.

J Med Chem. 2016 Feb 11;59(3):925-33. doi: 10.1021/acs.jmedchem.5b01354. Epub 2016 Jan 27.

8.

The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.

Kaufman KL, Jenkins Y, Alomari M, Mirzaei M, Best OG, Pascovici D, Mactier S, Mulligan SP, Haynes PA, Christopherson RI.

Oncotarget. 2015 Dec 1;6(38):40981-97. doi: 10.18632/oncotarget.5715.

9.

Potential Prognostic Value of Histone Deacetylase 6 and Acetylated Heat-Shock Protein 90 in Early-Stage Breast Cancer.

Park Y, Lee KS, Park SY, Kim JH, Kang EY, Kim SW, Eom KY, Kim JS, Kim IA.

J Breast Cancer. 2015 Sep;18(3):249-55. doi: 10.4048/jbc.2015.18.3.249. Epub 2015 Sep 24.

10.

Could the Anti-Chaperone VER155008 Replace Temozolomide for Glioma Treatment.

Shervington L, Patil H, Shervington A.

J Cancer. 2015 Jul 4;6(8):786-94. doi: 10.7150/jca.12251. eCollection 2015.

11.

Noninvasive molecular imaging of cell death in myocardial infarction using 111In-GSAO.

Tahara N, Zandbergen HR, de Haas HJ, Petrov A, Pandurangi R, Yamaki T, Zhou J, Imaizumi T, Slart RH, Dyszlewski M, Scarabelli T, Kini A, Reutelingsperger C, Narula N, Fuster V, Narula J.

Sci Rep. 2014 Oct 29;4:6826. doi: 10.1038/srep06826.

12.

Chemotherapeutic potential of 17-AAG against cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis.

Santos DM, Petersen AL, Celes FS, Borges VM, Veras PS, de Oliveira CI.

PLoS Negl Trop Dis. 2014 Oct 23;8(10):e3275. doi: 10.1371/journal.pntd.0003275. eCollection 2014 Oct.

13.
14.

Geldanamycin and Its Derivatives Inhibit the Growth of Myeloma Cells and Reduce the Expression of the MET Receptor.

Jurczyszyn A, Zebzda A, Czepiel J, Perucki W, Bazan-Socha S, Cibor D, Owczarek D, Majka M.

J Cancer. 2014 May 31;5(6):480-90. doi: 10.7150/jca.8731. eCollection 2014.

15.

Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions.

Jhaveri K, Ochiana SO, Dunphy MP, Gerecitano JF, Corben AD, Peter RI, Janjigian YY, Gomes-DaGama EM, Koren J 3rd, Modi S, Chiosis G.

Expert Opin Investig Drugs. 2014 May;23(5):611-28. doi: 10.1517/13543784.2014.902442. Epub 2014 Mar 26. Review.

16.

HPLC method development, validation and impurity characterization for an antitumor Hsp90 inhibitor-PU-H71 (NSC 750424).

Liu M, Wang J, Wu X, Wang E, Baptista D, Scott B, Liu P.

J Pharm Biomed Anal. 2014 Feb;89:34-41. doi: 10.1016/j.jpba.2013.10.021. Epub 2013 Oct 24.

17.

A novel therapeutic strategy for the treatment of glioma, combining chemical and molecular targeting of hsp90a.

Mehta A, Shervington L, Munje C, Shervington A.

Cancers (Basel). 2011 Dec 8;3(4):4228-44. doi: 10.3390/cancers3044228.

18.

A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation.

Chan KC, Ting CM, Chan PS, Lo MC, Lo KW, Curry JE, Smyth T, Lee AW, Ng WT, Tsao GS, Wong RN, Lung ML, Mak NK.

Mol Cancer. 2013 Oct 24;12(1):128. doi: 10.1186/1476-4598-12-128.

19.

Comparative proteomics in acute myeloid leukemia.

Luczak M, Kaźmierczak M, Hadschuh L, Lewandowski K, Komarnicki M, Figlerowicz M.

Contemp Oncol (Pozn). 2012;16(2):95-103. doi: 10.5114/wo.2012.28787. Epub 2012 May 29.

20.

Supplemental Content

Support Center